🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Clinical Trials in Spain / NCT07761884
Starting soon Not applicable

Early Implementation of Sacral Neuromodulation in Patients With Low Anterior Resection Syndrome.

NCT07761884 · tracked via the Priya Life Science Spain tracker
Phase
Not applicable
Started
2026-08
Last updated
2026-08-12

Condition(s) studied

Low Anterior Resection Syndrome (LARS)

Investigational drug(s) / intervention(s)

Sacral neuromodulation

Sacral neuromodulation: Sacral neuromodulation implantation within 120 days from discharge following rectal surgery or bowel reconstruction (ileostomy closure)

Study summary

A randomized, prospective, multicenter, open-label, pragmatic pilot study of patients with Low Anterior Resection Syndrome treated early (\<120 days after discharge following intestinal bypass reconstruction) with sacral nerve root neuromodulation, compared with another group receiving personalized conservative treatment as performed in routine clinical practice.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Adult patients (18 years of age or older) who are capable of signing the appropriate informed consent form. * Patients who have undergone an anterior rectal resection for rectal cancer, with an anastomosis, whether or not they have received neoadjuvant therapy, and who have bowel function, either via a direct anastomosis or following reconstruction of a lateral ileostomy. * Patients who experience more than 6 episodes of urgency and/or incontinence in the following two weeks after the screening visit, as recorded in a daily bowel diary. * Patients with a LARS score \>21 points (major or minor LARS). * Patients who report at least one symptom and one consequence as defined by the international definition. Exclusion Criteria: * Metastatic disease at the time of surgery. * Need for adjuvant chemotherapy at the time of assessment. * Active chemotherapy. * Patients with an ileostomy. * Intellectual or language-related difficulty in answering the questionnaires. * Refusal to participate in the study or failure to commit to follow-up visits. * Patients with contraindications for sacral neuromodulation implantation (those with pacemakers, active infections, or allergies to prosthetic materials). * Patients with active inflammatory bowel disease at the time of surgery. * Patients who have undergone other intestinal resections in addition to rectal resection.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Vall d'Hebron Barcelona Hospital Campus Barcelona Catalonia

More Hospital Universitari Vall d'Hebron Research Institute trials in Spain

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07761884 on ClinicalTrials.gov ↗ ← All trials in Spain